Thrombopoietin Receptor Agonists Market Trends

Growth Drivers

Rising Prevalence of Immune Thrombocytopenia Purpura (ITP)

According to the World Health Organization, the incidence of ITP among adults is estimated to be 32 cases per one million people every year. Increasing prevalence of the disease is projected to drive the thrombopoietin receptor agonist market growth during the forecast period. Frequent awareness activities by ITP support associations in the developed countries have been pivotal in making the masses aware about the disorder which could further fuel the market growth.

Increasing Support from Government Organizations for Medical Treatments

Treatment for immune thrombocytopenia purpura puts a financial burden on the patient and his family. To offset this burden, many governmental organizations and private firms are collaborating proactively to regulate the drug prices and assist the patients and their families. This financial assistance by the government is anticipated to boost the thrombopoietin receptor agonist market growth during the forecast period. Moreover, increasing investments for thrombopoietin receptor agonists research and development in order to invent sophisticated technology that helps in enhancing the drug performance is anticipated to drive the market growth in the coming few years.

Challenges

High Cost of Drug

When the technology involved in developing the thrombopoietin receptor agonists market becomes increasingly advanced, the cost of the drug increases significantly. Further, the cost of the skilled labor involved in developing such technologies may also increase in the coming years which is predicted to affect the market growth during the forecast period.

Stringent Safety Regulations

Thrombopoietin receptor agonists are generally well tolerated by most patients. However, side effects such as headache, fatigue, nausea and aminotransferase are estimated to negatively affect the market growth in future.